ALLVAS Endovascular Intervention Robot

ALLVAS™ represents Aopeng Medical’s flagship endovascular intervention robot, engineered as what the company describes as the world’s first universal platform for pan-vascular procedures. Unlike single-specialty vascular robots, ALLVAS™ addresses interventional needs across coronary, peripheral, neurovascular, and aortic territories from a unified system architecture.

Product Overview

Developed over nearly a decade of research and development, ALLVAS™ emerged from Aopeng Medical’s ambition to create broad robotic assistance for the full spectrum of endovascular interventions. The system adopts a master-slave control paradigm where physicians operate from a radiation-shielded console while robotic actuators manipulate catheters and guidewires at the patient table.

The platform distinguishes itself through an open architecture design that accommodates devices from multiple manufacturers across eight interventional specialties. This flexibility contrasts with existing approved systems like CorPath GRX, which focus primarily on coronary and peripheral procedures without the same breadth of neurovascular or aortic coverage.

ALLVAS™ employs a humanoid multi-manipulator design that simulates the coordinated hand movements of interventionalists and their assistants. This configuration enables both simple catheter-guidewire assistance and complex coordinated maneuvers such as stent deployment with simultaneous wire tracking and positioning.

Key Features

Multi-Modal Image Fusion: The system integrates with digital subtraction angiography (DSA) to generate real-time 3D vascular reconstructions with 0.1mm precision. AI algorithms automatically identify lesion locations and calculate optimal device pathways based on patient-specific anatomy.

Electromagnetic Damping Force Feedback: Aopeng Medical’s proprietary force feedback mechanism digitizes tactile sensations typically felt by operators during manual catheter manipulation. The electromagnetic damping rotational handle provides sub-millimeter operational accuracy while conveying resistance patterns that indicate vessel wall contact or device positioning.

Radiation Protection: Clinical data indicates over 90% reduction in operator radiation exposure compared to manual procedures. Physicians controlling from the shielded console avoid the cumulative X-ray exposure that contributes to increased cataract and cancer risks among interventionalists.

Automated Procedure Steps: The system can execute standardized catheter advancement and exchange sequences through preset programming, reducing reliance on individual operator technique and potentially shortening the learning curve for new device adoption.

5G Telesurgery Capability: ALLVAS™ has demonstrated remote operation with end-to-end latency below 80 milliseconds, enabling expert interventionalists to guide procedures at distant facilities.

Technical Specifications

Designed for pan-vascular interventional procedures, ALLVAS™ from Aopeng Medical delivers 0.1 mm 3D positioning precision, over 90% radiation reduction for operators, and 5G remote latency below 80 milliseconds.

Clinical Applications

ALLVAS™ addresses interventional procedures across multiple vascular territories:

Coronary Intervention (PCI): Percutaneous coronary intervention for atherosclerotic lesions, including stent deployment and balloon angioplasty. The coronary PCI indication has completed multicenter clinical trials and entered NMPA registration.

Peripheral Vascular Intervention: Treatment of occlusive and stenotic lesions in extremity arteries, including iliac, femoral, and tibial vessels. First-in-human peripheral procedures were completed in 2021.

Aortic Intervention (TEVAR/EVAR): Robot-assisted thoracic and abdominal endovascular aortic repair for aneurysm treatment. World-first robot-assisted TEVAR and EVAR procedures were performed in 2021.

Neurovascular Intervention: Thrombectomy for acute ischemic stroke and other cerebrovascular procedures. Aopeng Medical claims the world’s first robot-assisted neurovascular thrombectomy.

Venous Procedures: Vena cava filter implantation and retrieval procedures have been completed with robotic assistance.

The system can be deployed across cardiology, vascular surgery, neurology, neurosurgery, and interventional radiology departments, maximizing utilization from a single capital installation.

Regulatory Status

The inclusion in China’s Innovative Medical Device Catalog provides expedited review pathway advantages. Aopeng Medical had initially projected 2023 registration approval, though the timeline has extended into 2025-2026.

Clinical Evidence

First-in-human evaluations have been conducted at Shanghai Changhai Hospital under Professor Qing-Sheng Lu:

• Completed robot-assisted EVAR/TEVAR procedures with stable patient recovery
• Demonstrated precise lesion evaluation and positioning through DSA integration
• Achieved procedure outcomes meeting safety endpoints
• Published findings in peer-reviewed literature (European Radiology, 2023)

Clinical performance metrics from available data indicate:

• 40% reduction in complication rates
• 98.7% procedural success rate
• 96.5% reduction in operator radiation exposure during EVAR procedures

Competitive Positioning

The vascular interventional robot market includes several established and emerging systems:

ALLVAS™ differentiates through its multi-specialty platform approach and AI integration, though it enters the market later than established competitors. The over 90% domestic component rate provides potential cost advantages in the Chinese market.

Frequently Asked Questions

What makes ALLVAS different from CorPath or R-ONE?

ALLVAS™ is designed as a universal pan-vascular platform covering coronary, peripheral, neurovascular, and aortic procedures from a single system. Competitors like CorPath GRX focus primarily on coronary and peripheral indications. Additionally, ALLVAS™ incorporates AI-powered lesion identification and pathway planning that competitors have not emphasized to the same degree.

When will ALLVAS receive NMPA approval?

The coronary PCI indication has completed multicenter clinical trials and entered the NMPA registration phase as of 2025. The product’s inclusion in China’s Innovative Medical Device Catalog may facilitate expedited review. Exact approval timing remains dependent on regulatory review duration.

Can ALLVAS perform remote surgery?

Yes. In 2023, Aopeng Medical demonstrated China’s first 5G remote coronary intervention with ALLVAS™, achieving end-to-end latency below 80 milliseconds. This capability could enable expert interventionalists to guide procedures at facilities lacking specialist coverage.

What training is required to operate ALLVAS?

Aopeng Medical indicates the system features a standardized surgical operation process with a short learning curve. The automated procedure steps reduce reliance on individual technique, though specific training requirements and credentialing programs have not been publicly detailed.